Bright Minds Biosciences (DRUG) Income towards Parent Company (2023 - 2024)
Bright Minds Biosciences (DRUG) posted Income towards Parent Company of $35513.3 for Q4 2024, down 78.87% on a QoQ basis from $168091.4 in Q2 2024, and up 102.87% year-over-year from $17505.4 in Q1 2024.
Bright Minds Biosciences (DRUG) Income towards Parent Company (2023 - 2024) Analysis & Trends
Bright Minds Biosciences' Income towards Parent Company history runs 2 years deep, the most recent figure standing at $35513.3 for Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Bright Minds Biosciences | 681.98 Mn | 681.98 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 35,513.28 |
| Jun 30, 2024 | 168,091.41 |
| Dec 31, 2023 | -1.24 Mn |
| Jun 30, 2023 | -1.09 Mn |